Regulators Wrestle With Data Exclusivity For Pharmaceuticals Worldwide
By Tatum Anderson for Intellectual Property Watch
A debate over how long to give exclusive rights over data submitted by pharmaceutical companies to governments in order to receive approval to sell a drug in their markets is controversial not only in India, but worldwide.
